APVO | tickerfilter.com

Fundamental analysis

19%

Profitability 0%

Dept financing 20%

Liquidity 50%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-32.21%

1 Month

-60.85%

3 Months

-78.91%

6 Months

562.30%

1 Year

-69.02%

2 Year

-98.70%

Key data

Stock price

$1.01

P/E Ratio

0.00

DAY RANGE

$1.01 - $1.40

EPS

-$34.96

52 WEEK RANGE

$0.14 - $14.90

52 WEEK CHANGE

-$57.92

MARKET CAP

2.156 M

YIELD

N/A

SHARES OUTSTANDING

9.420 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

2.22

PUBLIC FLOAT

AVERAGE 10 VOLUME

$15,944,175

AVERAGE 30 VOLUME

$5,133,170

Company detail

CEO: Marvin L. White
Region: US
Website: aptevotherapeutics.com
Employees: 50
IPO year: 2016

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aptevo Therapeutics Inc. focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company also has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.

APVO - Aptevo Therapeutics Inc.